MedTrace Logo

Soluble Receptors for Advanced Glycation End-Products and PCI

NCT01867034 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-06-03

No results posted yet for this study

Summary

It is hypothesized that patients with low pre-PCI serum levels of sRAGE should receive DES implantation and/ or procedures taken to increase serum levels of sRAGE and/ or decrease the serum levels of AGE.

The purpose of this pilot study is to afford invasive cardiologists with additional evidenced based information to guide their decision as to which patients should receive a BMS or DES for coronary implantation.

The objectives of the study are to determine whether or not:

1. Patients with low pre-PCI serum levels of sRAGE who receive bare metal stents develop restenosis
2. Patients with high pre-PCI serum levels of sRAGE who receive bare metal stents will have reduced risk of the development of restenosis
3. Patients with low pre-PCI serum levels of sRAGE who receive drug eluting stents will have an increased risk of the development of restenosis

Conditions

  • Acute Coronary Syndrome

Interventions

OTHER

Drug Eluting Stent

Comparison of two stents to see which results in best outcome.

OTHER

Bare Metal Stent

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Erick McNair, PhD · University of Saskatchewan

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-03-31
Completion
2015-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01867034 on ClinicalTrials.gov